Gene therapy developers are under increasing pressure to advance their AAV-based therapeutics for clinical trials quickly. Leveraging Lonza expertise and the same tools and technologies implemented for our platform process, you can balance risk and speed, while maintaining high AAV productivity. Lonza’s Platform Process for AAV Manufacturing is established based on our proprietary suspension HEK293 cell line and plasmid vectors, proven to enhance AAV production. These materials are now available for use in your own laboratory.

View our poster

Download now
Latest content
Latest briefing from the Knowledge Center